A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells.
A remarkable approach to a specific tumor angiogenesis model in vivo is the use of alginate implants encapsulating tumor cells. However, this previously reported approach has often been questioned because of doubts regarding the relevance of hemoglobin at the alginate implant as a parameter of vascularization. In the present investigation, we examined whether or not the use of the blood pool agents FITC-dextran of high molecular weight would significantly improve the determination of vascularization at the alginate implant. In our experiments, we found a rapid distribution of FITC-dextran within the blood circulation of mice after i.v. bolus injection. The amount of FITC-dextran within alginate implants strongly correlated with the number of LL2 carcinoma cells or B16/F10 cells encapsulated. Even a low number of 10(3) cells per alginate implant led to a significantly increased accumulation of FITC-dextran. A more than 10-fold stimulation above that of controls was found with alginate implants containing 10(4) LL2 or B16/F10 tumor cells. Using the investigational compound AGM-1470 in different treatment schedules, we found that quantification of alginate implant anglogenesis with FITC-dextran is a sensitive method for the determination of angiogenesis inhibition. In conclusion, our results demonstrated that the use of FITC-dextran enables highly sensitive, quantitative measurement of blood vessel formation by alginate implants.
Hoffmann
J
J
Max-Delbrück Center for Molecular Medicine, Berlin, Germany.
Schirner
M
M
Menrad
A
A
Schneider
M R
MR
D000464:Alginates / Q000008:administration & dosage*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology; D018827:Carcinoma, Lewis Lung / Q000097:blood / Q000098:blood supply; D002292:Carcinoma, Renal Cell / Q000097:blood / Q000098:blood supply; D003510:Cyclohexanes; D003911:Dextrans / Q000097:blood / Q000737:chemistry; D004337:Drug Carriers; D005260:Female; D016650:Fluorescein-5-isothiocyanate; D005456:Fluorescent Dyes; D020723:Glucuronic Acid; D006490:Hemostatics / Q000008:administration & dosage*; D006603:Hexuronic Acids; D007680:Kidney Neoplasms / Q000097:blood / Q000098:blood supply; D051379:Mice; D008810:Mice, Inbred C57BL; D008819:Mice, Nude; D008863:Microspheres; D008970:Molecular Weight; D009369:Neoplasms / Q000097:blood / Q000098:blood supply*; D009389:Neovascularization, Pathologic / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology / Q000517:prevention & control; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D012717:Sesquiterpenes / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D000464:Alginates; D000903:Antibiotics, Antineoplastic; D003510:Cyclohexanes; D003911:Dextrans; D004337:Drug Carriers; D005456:Fluorescent Dyes; D006490:Hemostatics; D006603:Hexuronic Acids; D012717:Sesquiterpenes; D020723:Glucuronic Acid; D016650:Fluorescein-5-isothiocyanate; D000077609:O-(Chloroacetylcarbamoyl)fumagillol